Home › Therapeutic areas › Oncology › Hepatocellular Carcinoma
Hepatocellular Carcinoma (10 companies)
Companies with an active program in Hepatocellular Carcinoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADAG | Adagene | Oncology | 1 | Phase 2 | $99.4M | 10 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | $74.0M | 5 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $109M | 15 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $507M | 10 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $16.7B | 23 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $77.2M | 8 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | $51.7M | 4 |
| REPL | Replimune Group | Oncology | 1 | Approved | $1.87B | 5 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 1 | Phase 2 | $1.35B | 5 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $1.78B | 12 |
No companies match.